BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 20237798)

  • 1. Sodium channelopathies of skeletal muscle result from gain or loss of function.
    Jurkat-Rott K; Holzherr B; Fauler M; Lehmann-Horn F
    Pflugers Arch; 2010 Jul; 460(2):239-48. PubMed ID: 20237798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cold-induced defects of sodium channel gating in atypical periodic paralysis plus myotonia.
    Webb J; Cannon SC
    Neurology; 2008 Mar; 70(10):755-61. PubMed ID: 17898326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence study of genetically defined skeletal muscle channelopathies in England.
    Horga A; Raja Rayan DL; Matthews E; Sud R; Fialho D; Durran SC; Burge JA; Portaro S; Davis MB; Haworth A; Hanna MG
    Neurology; 2013 Apr; 80(16):1472-5. PubMed ID: 23516313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Slow inactivation: slow but not dull.
    Ruff RL
    Neurology; 2008 Mar; 70(10):746-7. PubMed ID: 18316687
    [No Abstract]   [Full Text] [Related]  

  • 5. Mutation spectrum and health status in skeletal muscle channelopathies in Japan.
    Sasaki R; Nakaza M; Furuta M; Fujino H; Kubota T; Takahashi MP
    Neuromuscul Disord; 2020 Jul; 30(7):546-553. PubMed ID: 32660787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and mutation spectrum of skeletal muscle channelopathies in the Netherlands.
    Stunnenberg BC; Raaphorst J; Deenen JCW; Links TP; Wilde AA; Verbove DJ; Kamsteeg EJ; van den Wijngaard A; Faber CG; van der Wilt GJ; van Engelen BGM; Drost G; Ginjaar HB
    Neuromuscul Disord; 2018 May; 28(5):402-407. PubMed ID: 29606556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A sodium channel knockin mutant (NaV1.4-R669H) mouse model of hypokalemic periodic paralysis.
    Wu F; Mi W; Burns DK; Fu Y; Gray HF; Struyk AF; Cannon SC
    J Clin Invest; 2011 Oct; 121(10):4082-94. PubMed ID: 21881211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of genetically confirmed skeletal muscle channelopathies in the era of next generation sequencing.
    Vivekanandam V; Jaibaji R; Sud R; Ellmers R; Skorupinska I; Germaine L; James N; Holmes S; Mannikko R; Jayaseelan D; Hanna MG
    Neuromuscul Disord; 2023 Mar; 33(3):270-273. PubMed ID: 36796140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel insights into the pathomechanisms of skeletal muscle channelopathies.
    Burge JA; Hanna MG
    Curr Neurol Neurosci Rep; 2012 Feb; 12(1):62-9. PubMed ID: 22083238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy in myotonic disorders and in muscle channelopathies.
    Meola G; Sansone V
    Neurol Sci; 2000; 21(5 Suppl):S953-61. PubMed ID: 11382195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Muscle channelopathies.
    Saperstein DS
    Semin Neurol; 2008 Apr; 28(2):260-9. PubMed ID: 18351527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Voltage-sensor sodium channel mutations cause hypokalemic periodic paralysis type 2 by enhanced inactivation and reduced current.
    Jurkat-Rott K; Mitrovic N; Hang C; Kouzmekine A; Iaizzo P; Herzog J; Lerche H; Nicole S; Vale-Santos J; Chauveau D; Fontaine B; Lehmann-Horn F
    Proc Natl Acad Sci U S A; 2000 Aug; 97(17):9549-54. PubMed ID: 10944223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered fast and slow inactivation of the N440K Nav1.4 mutant in a periodic paralysis syndrome.
    Lossin C; Nam TS; Shahangian S; Rogawski MA; Choi SY; Kim MK; Sunwoo IN
    Neurology; 2012 Sep; 79(10):1033-40. PubMed ID: 22914841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spectrum of Nondystrophic Skeletal Muscle Channelopathies in Children.
    Al-Ghamdi F; Darras BT; Ghosh PS
    Pediatr Neurol; 2017 May; 70():26-33. PubMed ID: 28325641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium Channelopathies of Skeletal Muscle.
    Cannon SC
    Handb Exp Pharmacol; 2018; 246():309-330. PubMed ID: 28939973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Periodic paralysis: understanding channelopathies.
    Lehmann-Horn F; Jurkat-Rott K; Rüdel R
    Curr Neurol Neurosci Rep; 2002 Jan; 2(1):61-9. PubMed ID: 11898585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotype-phenotype correlation and therapeutic rationale in hyperkalemic periodic paralysis.
    Jurkat-Rott K; Lehmann-Horn F
    Neurotherapeutics; 2007 Apr; 4(2):216-24. PubMed ID: 17395131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant sodium channels, myotonia, and propofol.
    England JD
    Muscle Nerve; 2001 Jun; 24(6):713-5. PubMed ID: 11360254
    [No Abstract]   [Full Text] [Related]  

  • 19. Human voltage-gated sodium channel mutations that cause inherited neuronal and muscle channelopathies increase resurgent sodium currents.
    Jarecki BW; Piekarz AD; Jackson JO; Cummins TR
    J Clin Invest; 2010 Jan; 120(1):369-78. PubMed ID: 20038812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlating phenotype and genotype in the periodic paralyses.
    Miller TM; Dias da Silva MR; Miller HA; Kwiecinski H; Mendell JR; Tawil R; McManis P; Griggs RC; Angelini C; Servidei S; Petajan J; Dalakas MC; Ranum LP; Fu YH; Ptácek LJ
    Neurology; 2004 Nov; 63(9):1647-55. PubMed ID: 15534250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.